GEORGE MATHEWS: Open Payments
NPI 1619980919 · HUMANSVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,194 in 48 payments from 11 companies in 2025. Trend: 2023 $1,639 · 2024 $2,020 · 2025 $1,194
Food & beverage: $1,194
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $506 |
| Novo Nordisk Inc | 3 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Neurocrine BioSciences, Inc. | 4 | $85 |
| Lilly USA, LLC | 3 | $58 |
| ABBVIE INC. | 3 | $50 |
| Alkermes, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
Products named: AUSTEDO XR, UZEDY, REXULTI, CAPLYTA, Ozempic, INGREZZA, VRAYLAR, KISUNLA.
Industry payments across MO — which companies pay providers there.
